Medtronic plc — Director's Dealing 2021

Feb 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Medtronic plc (MDT)
CIK: 0001613103
Period of Report: 2021-02-01

Reporting Person: Salmon Sean (EVP & Group President Diabetes)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-01	Ordinary Shares	A	1979	—	Acquired	30007	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-01	Stock Option (Right to Buy)	$111.18	A	16314	Acquired	2031-02-01	Ordinary Shares (16314)	Direct
2021-02-01	Performance Share Units	$	A	4947	Acquired		Performance Share Units (4947)	Direct

Footnotes

F1: This balance increased by 128 shares due to exempt transactions such as dividend reinvestment.

F2: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant.

F3: Each performance share unit represents a contingent right to receive one share of Medtronic common stock.

F4: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 4,947 shares will be issued. The actual number of shares to be issued could range from a low of 990 at minimum performance to a high of 9,894 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares.

F5: Vests on February 1, 2024.